1. Home
  2. AMSC vs GLUE Comparison

AMSC vs GLUE Comparison

Compare AMSC & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Superconductor Corporation

AMSC

American Superconductor Corporation

N/A

Current Price

$24.10

Market Cap

1.2B

ML Signal

N/A

Logo Monte Rosa Therapeutics Inc.

GLUE

Monte Rosa Therapeutics Inc.

N/A

Current Price

$9.35

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AMSC
GLUE
Founded
1987
2019
Country
United States
United States
Employees
400
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
AMSC
GLUE
Price
$24.10
$9.35
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
10
Target Price
★ $50.75
$25.38
AVG Volume (30 Days)
832.2K
★ 1.3M
Earning Date
11-04-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 1806.25
N/A
EPS
★ 0.27
N/A
Revenue
$900,000.00
★ $123,672,000.00
Revenue This Year
$22.94
N/A
Revenue Next Year
$16.19
N/A
P/E Ratio
$89.67
★ $72.42
Revenue Growth
N/A
★ 63.54
52 Week Low
$22.16
$8.95
52 Week High
$60.18
$25.77

Technical Indicators

Market Signals
Indicator
AMSC
GLUE
Relative Strength Index (RSI) 36.57 34.69
Support Level N/A N/A
Resistance Level $32.24 $12.00
Average True Range (ATR) 1.71 0.58
MACD -0.15 -0.07
Stochastic Oscillator 10.21 22.77

Price Performance

Historical Comparison
AMSC
GLUE

About AMSC American Superconductor Corporation

American Superconductor Corp generates the ideas, technologies, and solutions that meet the world's demand for smarter, cleaner, and energy. Through its Windtec Solutions, the company enables manufacturers to launch wind turbines quickly, effectively, and profitably. Through its Gridtec Solutions, the company provides engineering planning services and grid systems that optimize network reliability, efficiency, and performance. The company's segment includes Grid and Wind. It generates maximum revenue from the Grid segment.

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).

Share on Social Networks: